Participated · Seed · Jan 2026

STRM.BIO is a Cambridge, Massachusetts–based biotechnology company focused on a non-viral, cell-derived delivery modality for in vivo gene and cell therapies. Its megakaryocyte-derived vesicle (MV) platform is designed to safely and precisely carry complex genetic cargos directly to bone marrow, overcoming the immunogenicity and payload limits of viral and synthetic vectors. The company’s initial pipeline targets Fanconi anemia and other rare hematological disorders, while longer-term plans include in vivo CAR-T and broader immune-cell engineering applications. Recent funding activity has provided meaningful runway: $8 million in Series Seed 2 equity coupled with an $8.4 million ARPA-H contract brought total seed-stage capital raised in late 2025 to $16.4 million. STRM.BIO intends to use the proceeds to complete platform validation, advance preclinical programs toward the clinic, and prepare for a forthcoming Series A. Backers now include strategic pharma investors Recordati and Boehringer Ingelheim Venture Fund alongside Delos Capital and Blue Bay Capital. No revenue or clinical data have been disclosed to date.

Led · Series A · Jun 2021

xCures builds the Clinical Clarity Engine to aggregate, extract and structure fragmented patient medical records into decision-ready clinical data delivered via a web UI or developer API. The technology was developed over nearly a decade in oncology and is now used across clinical domains and workflows. xCures reports it has processed over 300 million medical records sourced from more than 550,000 healthcare locations, supporting clinical decisions for millions of patients across the U.S. The company links every extracted answer to its source document to enable traceable, evidence-grade decisions. Financially, xCures has raised more than $76 million in total funding following the $46 million Series B. The company plans to use the new capital to accelerate product development, expand its team, and scale adoption across provider, value-based care, diagnostics lab, and consumer health customers.

Led · Series A · Dec 2020

Perfood develops sinCephalea, a prescription digital therapeutic for migraine treatment that leverages personalized, blood sugar–stabilizing nutrition. The product translates scientific findings about individual glucose metabolism into digital health applications and pairs nutrition intervention with behavioral modulation features such as adherence management and patient education. Perfood tracks nutrition, activity, symptoms, medication and short-term glycemic responses for a limited two-week period, followed by a digital patient support program. The company plans to conduct clinical studies to advance its digital therapeutics and to expand the technology into other countries. Recent German legislation enabling prescription and reimbursement of digital health apps may support market access for sinCephalea. Perfood closed a €5M Series A to launch sinCephalea and support clinical and commercialization efforts.

Led · Seed · Aug 2020

Aignostics develops AI that transforms complex multimodal pathology data into actionable insights by combining proprietary access to clinical data, technologies, and scientific expertise. It builds products and services for precision medicine that support drug discovery, translational research, clinical trials, and CDx development. The company was established in 2018 as a spin-off from Charité Berlin and operates in Berlin and New York under CEO Viktor Matyas. Aignostics recently raised $34M in a Series B round to expand its product offerings and accelerate growth in the United States. It also plans to develop pathology foundation models in collaboration with Mayo Clinic and to deliver new offerings for biopharmaceutical clients. Aignostics develops explainable AI-powered digital pathology solutions that combine proprietary technology, a pathologist network, and access to key data modalities to build bespoke AI models for pharma and biotech clients. Its models cover key tissue staining technologies including hematoxylin-eosin (H&E), immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) to accelerate pre-clinical and translational research. The technology is intended to improve understanding of disease biology, mode of action, biomarkers, and drug response characteristics that are difficult to assess with traditional microscopy. Leadership includes CEO Viktor Matyas and CTO Dr. Maximilian Alber. The company originated from joint research at Charité and TU Berlin, entered the BIH Digital Health Accelerator in 2018 and spun out in early 2020. Aignostics plans to use the new funding to continue building its presence and team with a focus on the US market and maintains offices in Boston. Aignostics is a spin‑off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health that builds computational pathology tools based on Explainable AI. Its proprietary platform is designed to quantify morphological features, visualize model decisions, and uncover biomarkers that predict therapy response. The technology draws on research from Fraunhofer Society, Charité and TU Berlin and cites founders and contributors including Prof. Frederick Klauschen and Prof. Klaus‑Robert Müller. Aignostics says it has comprehensive access to key data modalities and pathologists, allowing development of bespoke AI models for clinical trials and companion/complementary diagnostics (CDx). The company will use the funds to expand its pharmaceutical research portfolio and to fund longer‑term projects aimed at developing CDx applications for clinical routine. Aignostics formally started in early 2018 and develops its applications in close collaboration with computer scientists, medical researchers and surgical pathologists.

Participated · Series B · Jun 2020

Founded in 2013 in Niel, Belgium, eTheRNA has developed an integrated set of proprietary capabilities providing an end‑to‑end solution to design, develop, and manufacture next‑generation mRNA products. Its platform includes proprietary molecular designs, lipid biochemistry expertise, customized lipid nanoparticle formulations (cLNPs), mRNA‑based T cell adjuvants, and advanced manufacturing processes. The company says it will leverage this suite of capabilities to serve partners in both early‑stage research and later‑stage development under a partnership‑driven business model. eTheRNA intends to use the funds from the recent financing to expand investment in its integrated mRNA technology platform and pursue new partnership initiatives. It plans to accelerate near‑term revenue growth through technology licensing and mRNA cGMP manufacturing services for multiple partners. Concurrent with the financing the company announced the departure of CEO Steven Powell and the appointment of COO Bernard Sagaert as interim CEO. eTheRNA, based in Niel, Belgium, develops immunotherapies from its proprietary mRNA TriMix platform, which comprises three mRNAs that together amplify immune responses. The company has also developed a proprietary lipid nanoparticle (LNP) platform to enable intravenous delivery of (neo)antigens. Its TriMix and LNP technologies have shown preclinical and clinical activity across major cancer types and are being positioned to act synergistically with standard-of-care treatments. eTheRNA plans to start clinical development of its internal intravenous mRNA delivery programs and to explore partnering opportunities. In infectious diseases, eTheRNA is leading an international consortium developing a cross-strain protective SARS-CoV-2 mRNA vaccine for high-risk populations. The company intends to use new financing to advance multiple therapeutic programs through to clinical proof-of-concept and to support continued development and commercialization of its proprietary mRNA technologies.